Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 50 | SFEBES2017 | Next issue

Society for Endocrinology BES 2017

Harrogate, UK
06 Nov 2017 - 08 Nov 2017

Card image cap
SfE BES 2017 will be on the 6-8 November 2016 in Harrogate, UK.

Oral Communications

Clinical Highlights

Mild autonomous cortisol excess in adrenal incidentalomas - metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients
1Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK; 2Institute of Applied Health Research, University of Birmingham, Birmingham, UK; 3Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece; 4Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland; 5Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia; 6Service d’Endocrinologie, Centre Hospitalier Universitaire, Hopital du Haut Leveque, Pessac, France; 7Department of Endocrinology, University Hospital Galway, Newcastle, Galway, Ireland; 8Department of Endocrinology, Haukeland University Hospital, Bergen, Norway; 9Endocrinology in Charlottenburg, Berlin, Germany; 10Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Technische Universitat Dresden, Dresden, Germany; 11Department of Internal Medicine I, Endocrine and Diabetes Unit, University Hospital, University of Wuerzburg, Wuerzburg, Germany; 12Department for Obesity, Reproductive and Metabolic Disorders, University of Belgrade, Belgrade, Serbia; 13Division of Internal Medicine I, University of Turin, San Luigi Hospital, Turin, Italy; 14Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, Munic, Germany; 15Division of Endocrinology, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ea0050oc2.1
A novel IGSF1 mutation in a large Irish kindred highlights the need for systematic familial endocrine screening in the IGSF1 deficiency syndrome
1University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, UK; 2Department of Paediatric Endocrinology and Diabetes, National Children’s Hospital, AMNCH, Dublin and University of Dublin, Trinity College Dublin, Dublin, Ireland; 3Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada; 4Department of Paediatric Endocrinology and Diabetes, Royal Belfast Hospital for Sick Children, Belfast, UK; 5Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Department of Surgery, University of Cambridge, Cambridge, UK; 6Department of Clinical Sciences and Community Health, Division of Endocrinology and Metabolism, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy; 7University College London Institute of Child Health, Developmental Endocrinology Research Group, Section of Genetics and Epigenetics in Health and Disease, Genetics and Genomic Medicine Programme, London, UK; 8Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada; These authors contributed equally
ea0050oc2.3
Additional value of 4D-CT in patients with primary hyperparathyroidism and negative conventional imaging; a reason to change primary imaging modality in patients over 60?
1Department of Endocrinology, Aberdeen Royal Infirmary, Aberdeen, UK; 2Department of Surgery, Aberdeen Royal Infirmary, Aberdeen, UK; 3Department of Radiation Protection, Aberdeen Royal Infirmary, Aberdeen, UK; 4Department of Clinical Radiology and Nuclear Medicine, Aberdeen Royal Infirmary, Aberdeen, UK.
ea0050oc2.5
Reduced early GLP-1 response in gestational diabetes is associated with hyperinsulinaemia and insulin resistance: a prospective case-control study
1Warwick Medical School, University of Warwick, Coventry, UK, 2George Eliot Hospital NHS Trust, Nuneaton, UK, 3University of Copenhagen, Copenhagen, Denmark.
ea0050oc2.6